Mometasone Furoate
Drug Approvals
(BANM, US Adopted Name, rINNM)
Pharmacopoeias. In Europe and US.
European Pharmacopoeia, 6th ed. (Mometasone Furoate). A white or almost white powder. Practically insoluble in water slightly soluble in alcohol soluble in acetone and in dichloromethane.
The United States Pharmacopeia 31, 2008 (Mometasone Furoate). A white to off-white powder. Soluble in acetone and in dichloromethane.
Profile
Mometasone furoate is a corticosteroid used topically for its glucocorticoid activity in the treatment of various skin disorders. It is usually used as a cream, ointment, or lotion containing 0.1%.
When applied topically, particularly to large areas, when the skin is broken, or under occlusive dressings, or when given intranasally, corticosteroids may be absorbed in sufficient amounts to cause systemic effects. The effects of topical corticosteroids on the skin are described. For recommendations concerning the correct use of corticosteroids on the skin, and a rough guide to the clinical potencies of topical corticosteroids.
A nasal suspension of mometasone furoate 0.05%, as the monohydrate, is given in the treatment and prophylaxis of the symptoms of allergic rhinitis. The usual adult dose is the equivalent of 100 micrograms of mometasone furoate in each nostril once daily, increased if necessary to 200 micrograms in each nostril daily. Once symptoms are controlled a dose of 50 micrograms in each nostril daily may be effective for maintenance. In the UK, the dose for children aged between 6 and 11 years is the equivalent of 50 micrograms in each nostril once daily. In the USA, similar doses may be given to treat allergic rhinitis in children from 2 years of age.
The nasal suspension is also given for the treatment of nasal polyps in patients 18 years and older the recommended initial dose in the UK is 100 micrograms into each nostril once daily, increased after 5 to 6 weeks to twice daily if needed. In the USA the recommended initial dose is 100 micrograms in each nostril twice daily, although once daily administration may be sufficient in some patients.
Mometasone furoate is used by dry powder inhaler for the prophylaxis of asthma. Doses may differ between countries and dosage units may be expressed differently, as either the amount of drug released per actuation or the amount delivered from the mouthpiece. UK licensed product information includes an initial dose of 400 micrograms inhaled once daily in the evening for mild to moderate asthma in adults and adolescents aged 12 years and older. This may be adjusted to a maintenance dose of 200 micrograms once or twice daily. In severe asthma, an initial dose of 400 micrograms twice daily is used, then titrated to the lowest effective dose once symptoms are controlled. US doses are provided in terms of the amount of drug released per actuation (an actuation that releases 110 micrograms delivers 100 micrograms from the mouthpiece). An initial dose of 220 micrograms once daily in the evening is used in adults and adolescents, aged 12 years and older, who have been treated with inhaled therapy only (bronchodilators or corticosteroids) this may be increased to a maximum of 440 micrograms daily as a single dose or 2 divided doses. Patients receiving oral corticosteroids may be started on 440 micrograms twice daily. Children aged 4 to 11 years may be given 110 micrograms once daily in the evening, regardless of prior therapy this is the maximum recommended daily dose.
Preparations
British Pharmacopoeia 2008: Mometasone Aqueous Nasal Spray Mometasone Cream Mometasone Ointment Mometasone Scalp Application
The United States Pharmacopeia 31, 2008: Mometasone Furoate Cream Mometasone Furoate Ointment Mometasone Furoate Topical Solution.
Proprietary Preparations
Argentina: Elocon Fenisona Metason Momeplus Nasonex Novasone Uniclar
Australia:: AllerMax † Elocon Nasonex Novasone
Austria: Asmanex Elocon Elovent Nasonex
Belgium: Elocom Nasonex
Brazil: Asmanexf Elocom Nasonex Topison
Canada: Elocom Nasonex
Chile: Dermenet Dermosona Elocom Flogocort Lisoder Momelab Nasonex Rinoval Uniclar
Czech Republic: Asmanex Elocom Nasonex
Denmark: Asmanex Elocon Nasonex
Finland: Asmanex Elocon Nasonex
France: Nasonex
Germany: Asmanex Ecural Nasonex
Greece: Asmanex Bioelementa Ecelecort Elocon Elovent Esine F-Din Fremomet Makiren Metason Mofur Molken Momecort Movesan Mozeton Nasamet Nasonex Pharmecort Yperod
Hong Kong: Elomet Nasonex Topcort
Hungary: Elocom Nasonex
India: Elocon Metaspray Momate Topcort
Indonesia: Dermovel Elocon Eloskin Elox Intercon Mefurosan Mesone Mofacort Mofulex Momet Motaderm Moteson Nasonex
Ireland: Asmanex Elocon Nasonex
Israel: Elocom Nasonex
Italy: Altosone Elocon Nasonex Rinelon Uniclar
Malaysia: Elomet Momate Nasonex
Mexico: Elica Elomet Elovent Rinelon Uniclar
The Netherlands: Asmanex Elocon Elovent Nasonex
Norway: Elocon Nasonex
New Zealand: Asmanex Bronconex Elocon
Philippines: Elica Elocon Momate Nasonex Rinelon
Poland: Elocom Elosone Nasonex
Portugal: Asmanex Elocom Elomet Elovent Nasomet Prospiril
Russia: Elocom Nasonex
South Africa: Elica Elocon Nasonex Rinelon
Singapore: Elomet Nasonex
Spain: Asmanexf Elica Elocom Nasonex Rinelon
Sweden: Asmanex Elocon Nasonex
Switzerland: Asmanex Elocom Nasonex
Thailand: Elomet Nasonex Rineloir †
Turkey: Elocon M-Furo Nasonex
UK: Asmanex Elocon Nasonex
USA: Asmanex Elocon Nasonex
Venezuela: Asmanex Cortynase Dergentil Elocon Eloconex † Elomet Nasonex Uniclar
Multi-ingredient
Argentina: Elosalic †
Austria: Elosalic
Chile: Velosalic
Czech Republic: Momesalic Monsalic †
Germany: Elosalic
Hong Kong: Elosalic
India: Momate-S
Indonesia: Elosalic
Poland: Elosalic
Portugal: Monsalic
Russia: Elocom-S
South Africa: Elosalic
Sweden: Elosalic
Thailand: Elosalic †
Turkey: Elosalic
Venezuela: Elosalic
This post has been viewed 23661 times.